- Company on track to dose first patient in 2Q 2024
- CTA marks progress in development of uTRACE® in prostate cancer under the collaboration between
Curasight and Curium
The CTA was submitted under the new application pathway Clinical Trials Information System (CTIS) and paves the way for patients to be recruited into the phase 2 trial of uTRACE® in prostate cancer which is part of the collaboration with Curium, announced in May 2023 .
"Today's news marks important progress in our efforts to develop uTRACE® for use in improving diagnosis for prostate cancer patients," said
About the Phase 2 trial with uTRACE® in prostate cancer
The primary objective of the phase 2 trial is to investigate
Patients in active surveillance are continuously monitored for changes in the aggressiveness of their prostate cancer and can be followed for years without identifying the need for treatment. The trial design is informed from research and earlier studies with uTRACE® as well as protocol discussions with the
About the uPAR diagnostic platform
The uTRACE® platform is part of Curasights uPAR theranostic solution, made up of its uTRACE® diagnostic technology and its uTREAT® targeted treatment technology. In prostate cancer, uTRACE® is presently developed for diagnostic purposes only.
For more information regarding
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
https://news.cision.com/curasight/r/curasight-a-s-submits-clinical-trial-application--cta--for-phase-2-trial-with-utrace--in-prostate-ca,c3895711
https://mb.cision.com/Main/19744/3895711/2501523.pdf
(c) 2023 Cision. All rights reserved., source